These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8938524)

  • 1. Micrometastases and transplantation.
    Sharp JG
    J Hematother; 1996 Oct; 5(5):519-24. PubMed ID: 8938524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Micrometastases in patients with colorectal cancer: markers for metastatic potential or proofs for residual disease].
    Iovchev I; Trifonov D; Popkharitov A; Khadzhipetkov F; Nikolov S
    Khirurgiia (Sofiia); 2004; 60(4-5):18-21. PubMed ID: 16042058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease: relevance for diagnosis and treatment of human malignancies.
    Hirsch-Ginsberg C
    Annu Rev Med; 1998; 49():111-22. PubMed ID: 9509253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis of minimal residual disease in autologous bone marrow transplantation].
    Jørgensen H; Bukh A; Hokland P; Ellegaard J; Madsen PS; Hokland M
    Nord Med; 1996 Dec; 111(10):344-7. PubMed ID: 8992466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First international ISHAGE symposium on minimal residual cancer.
    Pantel K; Moss TJ
    J Hematother; 1996 Oct; 5(5):511-7. PubMed ID: 8938523
    [No Abstract]   [Full Text] [Related]  

  • 6. [Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications].
    Toi M; Matsumoto G
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1315-36. PubMed ID: 10969586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease post-bone marrow transplantation for hemato-oncological diseases.
    Toren A; Rechavi G; Nagler A
    Stem Cells; 1996 May; 14(3):300-11. PubMed ID: 8724696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of minimal residual cancer cell research].
    Iinuma H; Watanabe T
    Nihon Geka Gakkai Zasshi; 2012 Mar; 113(2):177-84. PubMed ID: 22582577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease as the target for immunotherapy and gene therapy of cancer (review).
    Bubeník J; Símová J
    Oncol Rep; 2005 Nov; 14(5):1377-80. PubMed ID: 16211312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of minimal residual disease and mixed chimerism in a case of high-risk TEL/AML1+ acute lymphoblastic leukemia pre- and post-bone marrow transplantation. Czech Pediatric Haematology Working Group.
    Sedlácek P; Trka J; Zuna J; Hrusák O; Honzátková-Krsková L; Stary J
    Haematologica; 2000 Oct; 85(10):1100-2. PubMed ID: 11025608
    [No Abstract]   [Full Text] [Related]  

  • 11. Abstracts of the 2nd International Meeting on Minimal Residual Cancer, September 19-22, 1998, Berlin, Germany.
    Cytotherapy; 1999; 1(1):60-94. PubMed ID: 19847969
    [No Abstract]   [Full Text] [Related]  

  • 12. [Micrometastases in pediatric oncology].
    Bernard F; Aerts I; Margueritte G; Astruc J
    Bull Cancer; 2001 Jun; 88(6):577-80. PubMed ID: 11459704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Psychological adaptation to bone marrow transplantation].
    Delvaux N
    Rev Med Brux; 1992 Jun; 13(6):219-22. PubMed ID: 1631421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular cytogenetic monitoring of chimerism and minimal residual disease in patient with chronic myeloid leukemia after allogenic and syngenic bone marrow transplantation].
    Vinogradova OA; Savchenko VG; Domracheva EV; Liubimova LS; Ol'shanskaia IuV; Diachenko LV; Parovichnikova EN; Mendeleeva LP; Zakharova AV
    Ter Arkh; 2002; 74(7):38-44. PubMed ID: 12181833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?
    Grimwade D; Tallman MS
    Leuk Res; 2011 Jan; 35(1):3-7. PubMed ID: 20674017
    [No Abstract]   [Full Text] [Related]  

  • 16. [The identification of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications].
    Faulkner LB; Tamburini A; Tintori V; Paoli A; Tondo A; Bernini G; Medicina D; Brisigotti M; Corrias MV; Scaruffi P; Rosanda C; Lo Piccolo MS; Viscardi E; Milanaccio C; Garaventa A; De Bernardi B
    Pediatr Med Chir; 1998; 20(3):175-8. PubMed ID: 9744008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group.
    Mizuta S; Ito Y; Kohno A; Kiyoi H; Miyamura K; Tanimoto M; Takamatsu J; Naoe T; Morishima Y; Ueda R; Saito H
    Bone Marrow Transplant; 1999 Oct; 24(7):777-84. PubMed ID: 10516682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging.
    Negrin RS
    J Hematother; 1992; 1(4):361-8. PubMed ID: 1345678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and difficulties of patients encountered after autologous stem cell transplantation.
    Kav S; Aslan O; Tekin F; Yesil H; Meral C; Ozturk U; Bulut Z; Enaboifo A; Yazar B
    J BUON; 2009; 14(4):673-80. PubMed ID: 20148461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytokines following bone marrow transplantation: indications and controversies.
    Weinthal JA
    Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S10-4. PubMed ID: 8971400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.